$66.3 M

SLNO Mkt cap, 15-Oct-2021
Soleno Therapeutics Net income (Q1, 2021)-9 M
Soleno Therapeutics EBIT (Q1, 2021)-9.2 M
Soleno Therapeutics Cash, 31-Mar-202141.6 M
Soleno Therapeutics EV24.7 M
Get notified regarding key financial metrics and revenue changes at Soleno TherapeuticsLearn more
Banner background

Soleno Therapeutics Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

607.5k1.5m

Cost of goods sold

352.7k1.5m

Gross profit

254.8k(58.5k)

Gross profit Margin, %

42%(4%)

Sales and marketing expense

252.4k1.7m1.6m25.7k

R&D expense

2.2m4.5m5.2m3.1m7.2m16.3m23.2m

General and administrative expense

2.7m6.1m6.7m6.6m6.6m6.9m8.8m

Operating expense total

5.2m12.4m13.6m9.7m13.7m23.2m31.9m

EBIT

(5.2m)(12.2m)(13.6m)(12.2m)(14.3m)(23.5m)(36.3m)

EBIT margin, %

(2002%)(938%)

Interest expense

2.5m

Interest income

1.1k

Investment income

(478.0k)

Pre tax profit

(12.0m)13.7m(11.8m)(30.8m)(24.6m)

Income tax expense

21.7k(1.7m)

Net Income

(13.9m)(15.9m)(15.7m)(15.7m)(13.3m)(30.8m)(24.6m)

Soleno Therapeutics Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

8.0m5.5m2.7m17.1m23.1m20.7m49.2m

Accounts Receivable

156.1k133.3k

Prepaid Expenses

252.3k167.6k342.9k529.0k411.0k1.0m

Inventories

109.3k551.0k660.4k

Current Assets

8.3m6.4m3.8m18.0m24.7m21.1m50.2m

PP&E

57.6k85.7k102.6k22.9k12.0k22.0k19.0k

Goodwill

916.8k718.0k

Total Assets

8.4m8.2m5.6m39.0m43.2m38.2m65.0m

Accounts Payable

986.8k695.1k537.9k633.1k934.0k2.0m3.5m

Short-term debt

101.5k305.0k139.0k

Current Liabilities

1.3m3.2m1.7m1.7m1.9m5.0m8.6m

Long-term debt

139.0k

Total Debt

101.5k305.0k278.0k

Total Liabilities

2.1m12.5m12.7m23.2m19.4m

Common Stock

6.8k14.0k19.2k32.0k45.0k80.0k

Additional Paid-in Capital

60.6m89.5m101.7m140.5m157.4m172.7m227.9m

Retained Earnings

(71.0m)(86.2m)(98.3m)(114.0m)(127.0m)(157.8m)(182.4m)

Total Equity

(10.3m)3.2m3.4m26.5m30.4m14.9m45.5m

Financial Leverage

-0.8 x2.5 x1.6 x1.5 x1.4 x2.6 x1.4 x

Quarterly

USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

64.0k9.5m7.5m4.7m6.5m2.5m5.4m10.5m7.5m5.6m14.9m12.6m10.2m19.4m15.5m11.2m15.1m62.5m41.6m

Accounts Receivable

37.0k8.0k12.0k94.0k187.0k288.0k137.0k110.0k3.0k

Prepaid Expenses

186.0k260.0k311.0k225.0k216.0k157.0k217.0k261.0k246.0k145.0k423.0k248.0k327.0k603.0k471.0k375.0k572.0k505.0k921.0k

Inventories

206.0k277.0k376.0k653.0k774.0k703.0k855.0k164.0k

Current Assets

307.0k10.0m8.2m5.5m7.6m3.8m6.5m11.8m10.3m6.4m15.8m13.3m11.4m20.9m16.6m11.6m15.6m63.0m42.5m

PP&E

36.0k44.0k43.0k98.0k121.0k118.0k116.0k93.0k53.0k55.0k17.0k13.0k14.0k19.0k22.0k46.0k19.0k17.0k20.0k

Goodwill

718.0k718.0k718.0k718.0k718.0k

Total Assets

1.7m10.1m8.8m7.3m9.4m5.5m8.3m33.9m30.4m26.4m36.3m33.3m30.8m38.9m34.1m28.7m32.1m78.9m56.7m

Accounts Payable

1.2m621.0k989.0k953.0k1.3m957.0k862.0k935.0k1.0m642.0k1.1m981.0k1.2m1.3m1.7m1.7m3.5m3.7m4.7m

Dividends Payable

Short-term debt

315.0k298.0k57.0k

Current Liabilities

1.6m1.1m13.3m6.0m2.6m1.9m1.8m2.2m2.1m1.7m1.9m1.9m2.5m2.3m2.9m3.5m7.3m8.4m9.5m

Long-term debt

15.6m

Non-Current Liabilities

20.3m3.1m2.6m

Total Debt

15.6m315.0k298.0k57.0k

Total Liabilities

21.4m16.4m8.6m3.7m3.7m3.2m13.3m17.5m16.6m15.2m20.3m13.8m22.6m22.7m19.1m

Common Stock

1.0k7.0k8.0k12.0k15.0k15.0k15.0k47.0k48.0k10.0k20.0k21.0k21.0k32.0k32.0k32.0k45.0k80.0k80.0k

Additional Paid-in Capital

20.7m70.7m72.5m82.1m95.3m95.5m101.4m131.3m131.8m132.2m140.7m141.2m141.5m157.7m157.9m158.0m173.1m227.1m228.9m

Retained Earnings

(63.1m)(82.0m)(80.1m)(83.4m)(89.4m)(92.9m)(95.7m)(101.2m)(105.2m)(109.0m)(117.7m)(125.4m)(127.3m)(134.1m)(144.1m)(143.2m)(163.7m)(171.0m)(191.4m)

Total Equity

(42.4m)(11.3m)(7.6m)(1.3m)5.8m2.6m5.7m30.1m26.7m23.2m23.0m15.8m14.2m23.6m13.8m14.9m9.5m56.2m37.6m

Financial Leverage

0 x-0.9 x-1.1 x-5.6 x1.6 x2.1 x1.5 x1.1 x1.1 x1.1 x1.6 x2.1 x2.2 x1.6 x2.5 x1.9 x3.4 x1.4 x1.5 x

Soleno Therapeutics Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(13.9m)(15.9m)(15.7m)(13.3m)(30.8m)(24.6m)

Depreciation and Amortization

28.5k108.2k131.6k1.6m2.0m2.0m2.0m

Accounts Receivable

149.6k(156.1k)22.8k

Inventories

(109.3k)(441.7k)(109.4k)

Accounts Payable

353.9k211.9k(149.2k)190.6k249.0k1.1m1.5m

Cash From Operating Activities

(4.5m)(10.3m)(13.5m)(9.9m)(11.7m)(17.4m)(25.2m)

Purchases of PP&E

(30.7k)(55.8k)(38.7k)(2.6k)(8.0k)(21.0k)(7.0k)

Cash From Investing Activities

(30.7k)(1.3m)(38.7k)378.8k(180.0k)528.0k(7.0k)

Short-term Borrowings

(101.5k)

Long-term Borrowings

(2.0k)(17.0k)

Cash From Financing Activities

11.2m9.2m10.8m23.9m17.8m14.5m53.7m

Net Change in Cash

6.7m(2.5m)(2.8m)14.4m6.0m(2.4m)28.5m

Income Taxes Paid

800.0

Soleno Therapeutics Ratios

USDQ3, 2014